[go: up one dir, main page]

AR072066A1 - Uso de composicion que comprende oligosacaridos no digeribles - Google Patents

Uso de composicion que comprende oligosacaridos no digeribles

Info

Publication number
AR072066A1
AR072066A1 ARP090102047A ARP090102047A AR072066A1 AR 072066 A1 AR072066 A1 AR 072066A1 AR P090102047 A ARP090102047 A AR P090102047A AR P090102047 A ARP090102047 A AR P090102047A AR 072066 A1 AR072066 A1 AR 072066A1
Authority
AR
Argentina
Prior art keywords
composition
oligosacarids
digerable
includes non
administration
Prior art date
Application number
ARP090102047A
Other languages
English (en)
Inventor
Jurgen Jelinek
Gunther Boehm
Bernd Stahl
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of AR072066A1 publication Critical patent/AR072066A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Uso de la composicion caracterizado porque la composicion comprende al menos un oligosac rido no digerible que se selecciona del grupo que consiste en galactooligosac rido, fructooligosac rido, y oligosac rido de  cido uronico en la preparacion de una composicion para evitar la administracion topica de corticosteroides y/o la prevencion de la administracion de inhibidor de calcineurina.
ARP090102047A 2008-06-06 2009-06-05 Uso de composicion que comprende oligosacaridos no digeribles AR072066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08157767 2008-06-06

Publications (1)

Publication Number Publication Date
AR072066A1 true AR072066A1 (es) 2010-08-04

Family

ID=39691169

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102047A AR072066A1 (es) 2008-06-06 2009-06-05 Uso de composicion que comprende oligosacaridos no digeribles

Country Status (7)

Country Link
US (1) US20110098246A1 (es)
EP (1) EP2293801A1 (es)
CN (1) CN102056613A (es)
AR (1) AR072066A1 (es)
BR (1) BRPI0914865A2 (es)
RU (1) RU2500408C2 (es)
WO (1) WO2009148315A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3029114B1 (fr) * 2014-12-01 2017-01-13 United Pharmaceuticals Composition nutritionnelle infantile dans le traitement de la dermatite atopique et de ses symptomes
WO2019026844A1 (ja) * 2017-08-01 2019-02-07 久光製薬株式会社 貼付剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335023B1 (en) * 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
DE10057976B4 (de) * 2000-11-22 2005-02-03 Südzucker AG Mannheim/Ochsenfurt Verfahren zur Herstellung von Pektinhydrolyseprodukten
EP1597978A1 (en) * 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
CN101039699B (zh) * 2004-10-15 2011-07-27 柳署弘 用于减小药物化合物毒性的方法和组合物
EP1776877A1 (en) * 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora

Also Published As

Publication number Publication date
WO2009148315A1 (en) 2009-12-10
CN102056613A (zh) 2011-05-11
EP2293801A1 (en) 2011-03-16
RU2500408C2 (ru) 2013-12-10
BRPI0914865A2 (pt) 2015-11-03
US20110098246A1 (en) 2011-04-28
RU2010154665A (ru) 2012-07-20

Similar Documents

Publication Publication Date Title
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
BR112014017650A2 (pt) composições e uso de ésteres de forbol
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
MX346335B (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
UY32644A (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
WO2009063222A3 (en) Solid compositions
MX2007016462A (es) Composiciones topicas para tratar la piel.
DOP2011000354A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
MX380787B (es) Composiciones de corticosteroides administradas oralmente.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
AR061989A1 (es) Combinacion de peroxido de adapaleno y benzoilo para el tratamiento de lesiones de acne
BR112012012960A2 (pt) supositório para administração retal, vaginal ou uretral e seus usos.
BR112012033077B8 (pt) Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
CU20120171A7 (es) Triazolopiridinas sustituidas
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
AR086543A1 (es) Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
BR112014009365A2 (pt) método para inibição da atividade de deubiquitinação
BR112014016661A2 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
HRP20150949T1 (hr) UPORABA 24-norUDCA
AR065316A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.
WO2008099144A3 (en) Tgf-beta stimulant and further agent to reduce side effects

Legal Events

Date Code Title Description
FB Suspension of granting procedure